Open access
228
Views
8
CrossRef citations to date
0
Altmetric
Clinical Trial Report
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
Qing An1 Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Jiangsu, China
, Yingxin Zheng2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected];3 Obstetrics and Gynecology Hospital of Fudan University; Shanghai, China
, Yirong Zhao2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected]
, Tao Liu2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected]
, Huaizu Guo2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected]
, Dapeng Zhang2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected];3 Obstetrics and Gynecology Hospital of Fudan University; Shanghai, China;4 School of Pharmacy, Liaocheng University, Liaocheng, China, [email protected]
, Weizhu Qian5 Shanghai Key Laboratory of Cell Engineering, Shanghai, China
, Hao Wang5 Shanghai Key Laboratory of Cell Engineering, Shanghai, China
, Yajun Guo2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected];4 School of Pharmacy, Liaocheng University, Liaocheng, China, [email protected];6 School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China;7 Institute of Molecular and Cell Biology, Proteos, Singapore
, Sheng Hou2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected];4 School of Pharmacy, Liaocheng University, Liaocheng, China, [email protected]Correspondence[email protected] [email protected]
& Jing Li2 State Key Laboratory of Antibody Medicine and Targeted Therapy; Shanghai, China, [email protected]; [email protected];8 Shanghai Zhangjiang Biotechnology Co., Ltd; Shanghai, China, [email protected]Correspondence[email protected] [email protected]
show all
Pages 791-805
|
Published online: 12 Mar 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.